Updated Amivantamab and Lazertinib Combination Data Demonstrate Durable Responses and Clinical Activity for Osimertinib-Relapsed Patients with EGFR-Mutated Non-Small Cell Lung Cancer
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced updated data from the Phase 1 CHRYSALIS study showing treatment with amivantamab in combination with lazertinib led to a median duration of response (DOR) of 9.6 months in chemotherapy-naïve patients with non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib. These data, which will be presented in an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 4, also provide new insights on the importance of biomarkers to identify a subgroup of patients more likely to respond to amivantamab and lazertinib (Abstract #9006). Results from the CHRYSALIS study have led to new studies to further evaluate the potential of amivantamab and lazertinib combination therapy, which include the Phase 3 MARIPOSA study and Phase 1/1b CHRYSALIS-2 study.,“Typically, patients whose disease no longer responds to osimertinib therapy would have little opportunity to seek additional treatments, other than chemotherapy. However, the durable responses we are seeing with the combination of amivantamab and lazertinib suggest an additional targeted option may be possible,” said Byoung Chul Cho, M.D., Ph.D., Yonsei Cancer Center, Yonsei University College of Medicine in Seoul, South Korea, and lead stu...
Urachal cancer, a rare malignancy, constitutes
South African researchers report ‘extensive but incomplete’ reduction in immune protection
A South African study found that Omicron may dull the power of coronavirus vaccines, but hinted that booster shots might help.
Charity Spread a Smile has put on a tea party for seriously ill children who spent lockdown in hospital.
A year ago today, Margaret Keenan became the first person in the world to receive the Pfizer/BioNTech covid-19 vaccine outside of a clinical trial. 12 months and billions of shots later, several countries are already on a third round of coronavirus vaccinations
Nearly all of Atrium Health's employees — 99.5% — are in compliance with the system's Covid-19 vaccination mandate, CEO Gene Woods said.
AbstractIntroductionTrends in the use of short-course radiation therapy (RT) for rectal cancer in Australia are unknown. The purpose of this study was to compare short-course RT and long-course chemoradiation (CRT) utilisation in the neoadjuvant treatment of rectal cancer in New South Wales (NSW).MethodsPatients who received neoadjuvant RT (2009 –2014) for rectal cancer were identified from the NSW Central Cancer Registry. Univariate and multivariable analyses were performed to investigate factors associated with receipt of short-course RT.ResultsA total of 1196 (81%) patients received long-course CRT, and 274 (19%) ...
JULIA BRADBURY has bravely shared her journey while she battles breast cancer.The Countryfile and Watchdog host has admirably undergone a mastectomy in a bid to rid herself of the dreadful disease. Most recently the star took to social media where she was seen eating a particular fruit that she claimed helps to reduce cancer risks.
Clinacanthus nutans is an economically important medicinal plant that can be found grown in many countries in the Asian region. Useful medicine properties such as anti-cancer, anti-bacteria, and anti-viral, backed by its high content of phytochemical compounds such vitexin, isovitexin, stigmasterol and lupeol has increased the demand for C. nutans in the market. Extensive work had been carri...
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with ...
More News: Adenocarcinoma | Alimta | Allergy & Immunology | Biotechnology | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Cardiology | Cardiovascular | Chemotherapy | Clinical Trials | Conferences | Cytology | Databases & Libraries | Dermatitis | Dermatology | Economics | Epidemiology | France Health | Genetics | Health Management | Heart | Hypertension | Infectious Diseases | International Medicine & Public Health | Learning | Legislation | Lung Cancer | Neurology | Neuroscience | Non-Small Cell Lung Cancer | Oral Cancer | Pharmaceuticals | Pulmonary Hypertension | Science | Singapore Health | Skin Cancer | South Korea Health | Squamous Cell Carcinoma | Statistics | Study | Universities & Medical Training | Vaccines | Websites | WHO